Lv4
500 积分 2021-11-15 加入
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
1天前
已完结
Long-term immune related adverse events
1天前
已完结
Clinical and translational attributes of immune-related adverse events
1天前
已完结
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
1天前
已完结
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
1天前
已完结
Beyond immune checkpoint blockade: emerging immunological strategies
1天前
已完结
Tumour burden and efficacy of immune-checkpoint inhibitors
1天前
已完结
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
1天前
已完结
Immune checkpoint inhibitors in melanoma
1天前
已完结
Linking macrophage metabolism to function in the tumor microenvironment
1个月前
已完结
皖公网安备34019202002308
